Ardelyx Inc. (ARDX)

Name: Ardelyx Inc. (ARDX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Ardelyx Inc. (ARDX)

Stock Card

$3.81

$-0.01 (-0.26%)

As on 28-Aug-2026 16:20EDT

Market cap

$984 Mln

Revenue (TTM)

$451 Mln

P/E Ratio

P/B Ratio

6.6

Div. Yield

0 %

Ardelyx (ARDX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 3.75 High: 3.90

52 Week Range

Low: 3.73 High: 8.40

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.4 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

130.9
Debt to Equity

1.7
Book Value

$0.6
EPS

$-0.2
Face value

--
Shares outstanding

258,187,572

10 Years Aggregate

CFO

$-756.67 Mln

EBITDA

$-740.92 Mln

Net Profit

$-781.55 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Ardelyx (ARDX)	-34.6	-24.7	-38.2	-38.4	-1.1	21.3	-9.5
BSE Sensex^*	-9.3	-1.4	2.7	-3.7	5.7	6.2	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | *As on 31-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
Ardelyx (ARDX)	15.0	-18.1	117.5	159.1	-83.0	-13.8	319.3
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Ardelyx (ARDX)	3.8	983.7	450.9	-55.7	-6.2	-35.3	--	6.6
Arrowhead Pharmaceuticals (ARWR)	84.9	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Ascendis Pharma A/S - ADR	247.9	16,261.1	1,054.4	755.9	5.7	--	19	9.8
Cytokinetics Inc (CYTK)	72.1	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	54.5	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	105.4	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	351.5	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	533.8	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	600.7	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	344.8	9,625.4	0.0	-339.1	--	-30.6	--	7.6

Shareholding Pattern

View Details

About Ardelyx (ARDX)

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with... irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Read more

President, CEO & Director

Mr. Michael G. Raab
President, CEO & Director

Mr. Michael G. Raab
Headquarters

Waltham, MA
Website

https://www.ardelyx.com

FAQs for Ardelyx (ARDX)

What is the current share price of Ardelyx Inc (ARDX) Today?

The share price of Ardelyx Inc (ARDX) is $3.81 (NASDAQ) as of 28-Aug-2026 16:20 EDT. Ardelyx Inc (ARDX) has given a return of -1.11% in the last 3 years.

What is the current PB & PE ratio of Ardelyx Inc (ARDX)?

Since, TTM earnings of Ardelyx Inc (ARDX) is negative, P/E ratio is not available.
The P/B ratio of Ardelyx Inc (ARDX) is 6.60 times as on 28-Aug-2026, a 27 premium to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.